Tirzepatide pen 10 mg (GLP1+GIP)

Tirzepatide Pen 10 mg - characteristics

Tirzepatide pen 10 mg refers to the formulation used in clinical trials of the synthetic peptide analogue tirzepatide. The substance is a dual agonist of GIP and GLP-1 receptors and belongs to the modified incretin peptides.

Thirzepatide is a molecule composed of 39 amino acids whose structure was designed to increase metabolic stability and prolong duration of action. It contains modifications that limit enzymatic degradation and a lipid component that allows reversible binding to albumin. The molecular weight of the compound is approximately 4813 Da.

In a laboratory context, the term Tirzepatide pen refers to the delivery system used in the study, while the molecule itself remains the subject of pharmacological and molecular analyses.

Thirzepatide pen - mechanism of action (molecular approach)

The mechanism of action of tirzepatide pen 10 mg is due to the properties of the tirzepatide molecule itself as an agonist of incretin receptors belonging to the GPCR family.

Activation of GIP and GLP-1 receptors

Tirzepatide pen exhibits the ability to simultaneously activate GIPR and GLP-1R. The synergistic effect of this dual activity was analyzed in clinical studies:

• glucose-dependent insulin secretion,
• inhibition of glucagon secretion,
• Regulation of glucose homeostasis.

Effect on gastric emptying

In clinical models, tirzepatide pen 10 mg was associated with slowed gastrointestinal motility, which correlated with prolonged gastric emptying time.

Modulation of central satiety pathways

GLP-1 receptors are present in structures of the central nervous system. The study evaluated the effects of tirzepatide pen on signals related to the regulation of appetite and energy balance.

Metabolic parameters

Clinical data on tirzepatide pen included analysis of changes in body weight, glycemic indices and lipid parameters in relation to dose (5 mg, 10 mg, 15 mg) and follow-up time.

Tirzepatide pen in clinical trials

One of the most cited research projects is SURMOUNT-1, which evaluated the effect of tirzepatydu in subjects in a research protocol who were overweight or obese.

The 72-week follow-up showed statistically significant differences from placebo in terms of dose-dependent changes in body weight on a weekly schedule. Tirzepatide pen was also analyzed for:

• HbA1c changes,

• fasting glucose levels,

• lipid profile,

• cardio-metabolic parameters.

Separate phase 3 studies compared tirzepatide with other GLP-1 agonists in a population with type 2 diabetes.

Safety and side effects - data reported in studies

In clinical trials for tirzepatide pen 10 mg, gastrointestinal symptoms were most commonly reported, including:

• nausea,
• vomiting,
• diarrhea,
• constipation,
• feeling of fullness.

The incidence of adverse effects was dose and escalation phase dependent. These data are from controlled clinical trials and remain subject to further long-term analysis.

Research application

In a laboratory context, the tirzepatide pen is treated as:

• A model GIP/GLP-1 receptor agonist,
• GPCR signaling research tool,
• reference compound in analyses of glucose metabolism and energy regulation.

The product is intended for research and analytical applications only.
It is not a dietary supplement or food product.

See also SLU-PP-332 60caps/500mcg.